Tracking Treatable Tissues: Change in qMRI Biomarkers and Future Cartilage Loss

追踪可治疗组织：qMRI 生物标志物的变化和未来的软骨损失

• 批准号: 9762584
• 负责人: JEFFREY W DURYEA
• 金额: $ 53.31万
• 依托单位: UNIVERSITY OF ARIZONA
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-05 至 2021-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9762584
• 关键词: Affect; Aging; Biological Markers; Bone Marrow; Cartilage; Clinical; Clinical Trials; Complex; Data; Degenerative polyarthritis; Development; Diagnostic radiologic examination; Disease; Disease Progression; Drug Design; Economic Burden; Eligibility Determination; FDA approved; Femur; Functional disorder; Funding; Future; Growth; Image; Incidence; Individual; Joints; Knee; Knee Osteoarthritis; Knee bone; Lateral; Lesion; Magnetic Resonance Imaging; Medial; Methodology; Musculoskeletal Diseases; Obesity Epidemic; Operative Surgical Procedures; Outcome; Outcome Measure; Pain; Patient Outcomes Assessments; Pharmaceutical Preparations; Population; Prevention; Public Health; Reading; Recommendation; Resolution; Resources; Risk; Sampling; Signal Transduction; Structure; Synovial Membrane; Synovitis; Testing; Therapeutic; Time; Tissues; United States National Institutes of Health; Western Ontario and McMaster Universities Arthritis Index; Work; aging population; base; bone; clinically significant; cohort; design; disability; disabling disease; disabling symptom; effusion; follow-up; functional decline; functional disability; improved; knee replacement arthroplasty; pre-clinical; prevent; research study; societal costs; soft tissue; subchondral bone; tibia

PROJECT SUMMARY/ABSTRACT Osteoarthritis (OA) is a complex, heterogeneous condition that is a major public health problem, the most common cause of disability in the aging population and is associated with a large economic burden. The pathophysiology of OA affects the whole joint, with breakdown of cartilage, associated changes in the subchondral bone and adjacent soft tissue that leads to debilitating symptoms such as pain. With the aging of the population and the epidemic of obesity, the public health impact of OA, especially knee OA, has and will continue to increase dramatically, but unfortunately, there are no FDA-approved disease-modifying OA drugs (DMOADs), i.e., drugs designed to impede or prevent the OA-related structural changes to cartilage and bone. This has been due to a lack of understanding of the relationship between features of OA and disease progression. MRI, however, has improved our understanding of the relationship between histopathologic changes and the structural changes to cartilage, subchondral bone and the surrounding soft tissues of the joint in OA. As such MRI represents an improvement over plain knee radiographs, which are both insensitive and nonspecific to critical changes in joint structure in the development and progression of OA. The objective of this work is to understand the impact of the trajectory of BMLs and ES on downstream clinical outcomes, including cartilage loss and disability, over the short-term (i.e., two years later) and long-term (i.e., six years later). Analysis of the trajectory of BMLs and ES will take into account the quantitative volume at baseline and the quantitative change in volume over time. The specific aims of this study are: To evaluate the impact of the trajectory of MRI-detected bone marrow lesions (BMLs) and effusion synovitis (ES) on subsequent cartilage loss; and to evaluate the impact of the trajectory of MRI-detected BMLs and ES on knee-specific disability.

项目摘要/摘要 骨关节炎（OA）是一种复杂的，异质的疾病，是一个主要的公共卫生问题，最多是 老龄化人口残疾的常见原因，与巨大的经济负担有关。这 OA的病理生理影响整个关节，随着软骨的细分，相关的变化 软骨下骨和邻近的软组织会导致诸如疼痛之类的症状使人衰弱。随着老化的 肥胖的人口和流行，OA的公共卫生影响，尤其是膝盖OA的影响 继续显着增加，但不幸的是，没有FDA批准的疾病改良药物 （DMOADS），即旨在阻碍或防止OA相关的软骨和骨骼的结构变化的药物。 这是由于缺乏对OA和疾病特征之间关系的了解 进展。但是，MRI已提高了我们对组织病理学之间关系的理解 变化以及对软骨，软骨下骨和关节周围软组织的结构变化 在OA中。因此，MRI代表了对普通膝盖X光片的改进，这既不敏感又 非特异性与OA发展和进展的关节结构的关键变化。 这项工作的目的是了解BML和ES轨迹对下游临床的影响 在短期（即两年后）和长期（即， 六年后）。对BML和ES的轨迹的分析将考虑到定量体积 基线和数量随时间变化的变化。 这项研究的具体目的是：评估MRI检测的骨髓轨迹的影响 随后的软骨损失的病变（BML）和积液滑膜炎（ES）；并评估 MRI检测的BML和ES的轨迹在膝关节特异性的残疾上。